about_us - Novo Nordisk A/S

Novo Nordisk in short

Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.

Headquartered in Denmark, Novo Nordisk employs approximately 32,000 employees in 75 countries, and markets its products in 179 countries.

Novo Nordisks B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).

A passion for helping people

The story of Novo Nordisk goes back more than 80 years. It began when August Krogh, a Nobel Prize-winning professor at the University of Copenhagen, decided he wanted to start producing a revolutionary new medical preparation called insulin.

Novo Nordisk's history

Our business philosophy

The Triple Bottom Line -
our way of doing business
We believe that a healthy economy, environment and society are fundamental to long-term business success. This is why we manage our business in accordance with the Triple Bottom Line business principle and pursue business solutions that maximise value to our stakeholders as well as our shareholders.

In practice, this means that any decision should always seek to combine three considerations: is it financially, socially and environmentally responsible? This way, we continuously optimise our business performance and enhance our contribution to the societies we operate in.

If you are more interested in our way of doing business, we suggest you read these pages:
Our priorities
Our positions
Our reporting
Or look here for further information on how we manage sustainably.